Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-26-048793
Filing Date
2026-04-24
Accepted
2026-04-24 20:12:50
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11303
2 EXHIBIT 99.1 tm2612362d1_ex99-1.htm EX-99.1 4036
  Complete submission text file 0001104659-26-048793.txt   17246
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Subject) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45969 | Film No.: 26896233
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017
Business Address 767 THIRD AVENUE, 17TH FLOOR NEW YORK NY 10017 646-970-2123
Paradigm Biocapital Advisors LP (Filed by) CIK: 0001855655 (see all company filings)

EIN.: 851451055 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G